# Could GLP-1s Help with Fertility in Men and Women?
GLP-1 receptor agonists like semaglutide and tirzepatide are gaining attention for potential fertility benefits beyond their proven weight loss effects. Recent research suggests these medications may improve reproductive outcomes in both men and women, though the evidence remains preliminary.
Weight plays a direct role in fertility. Obesity disrupts hormone production, reduces sperm quality, and interferes with ovulation and egg quality. When GLP-1 medications help patients lose significant weight, they often restore hormonal balance naturally. Studies show men who lose weight through these drugs experience improvements in sperm count and motility. Women frequently regain regular menstrual cycles after dropping pounds with GLP-1 therapy, addressing one common cause of infertility.
Beyond weight loss mechanics, researchers are exploring whether GLP-1s offer direct reproductive benefits. Some evidence suggests these drugs may reduce inflammation and improve metabolic function in ways that support fertility independent of weight loss alone. A 2024 analysis published in reproductive medicine journals noted that patients on GLP-1s showed better insulin sensitivity, a factor linked to improved ovulation rates and egg quality in women with polycystic ovary syndrome (PCOS).
For men, emerging data indicates GLP-1s may protect testicular function and improve overall sexual health markers. The mechanism likely involves better blood vessel function and reduced oxidative stress, factors that affect erectile function and sperm production.
However, practitioners stress that most evidence comes from weight loss studies rather than fertility-specific trials. Fertility specialists recommend GLP-1s primarily as tools to achieve healthy weight before conception, not as standalone fertility treatments. Women planning pregnancy should discuss timing carefully with doctors since these medications require discontinuation during pregnancy.
The fertility benefits appear strongest in patients with obesity-related infertility, particularly those with PCOS